Zions Bancorporation N.A. Has $1.85 Million Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Zions Bancorporation N.A. grew its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 16.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,882 shares of the medical technology company's stock after purchasing an additional 28,702 shares during the period. Zions Bancorporation N.A. owned about 0.14% of Alphatec worth $1,853,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its stake in shares of Alphatec by 0.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company's stock valued at $2,873,000 after buying an additional 1,120 shares during the period. Rhumbline Advisers lifted its position in Alphatec by 1.3% in the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock worth $1,277,000 after purchasing an additional 1,746 shares during the period. Swiss National Bank boosted its stake in Alphatec by 1.1% during the fourth quarter. Swiss National Bank now owns 207,200 shares of the medical technology company's stock worth $1,902,000 after buying an additional 2,300 shares in the last quarter. R Squared Ltd bought a new stake in Alphatec in the 4th quarter valued at $29,000. Finally, Atria Investments Inc raised its stake in shares of Alphatec by 20.3% in the 4th quarter. Atria Investments Inc now owns 23,585 shares of the medical technology company's stock valued at $217,000 after buying an additional 3,976 shares in the last quarter. Institutional investors own 66.35% of the company's stock.

Remove Ads

Insider Buying and Selling

In other news, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Scott Lish sold 27,453 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock valued at $3,828,060 over the last ninety days. Insiders own 22.80% of the company's stock.

Alphatec Price Performance

Shares of NASDAQ:ATEC traded up $0.14 during midday trading on Friday, reaching $10.19. The company's stock had a trading volume of 1,099,336 shares, compared to its average volume of 1,976,462. The business's fifty day simple moving average is $10.86 and its 200-day simple moving average is $8.99. The company has a market capitalization of $1.47 billion, a P/E ratio of -7.96 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.54.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several recent research reports. Piper Sandler lifted their target price on shares of Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Needham & Company LLC restated a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Finally, StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.67.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.